JACKSONVILLE, Fla., Sept. 2, 2022 /PRNewswire/ — The urgency of treating chronic wounds and foot ulcers cannot be ignored. In recognition of Peripheral Artery Disease (PAD) Awareness Month, Healogics® is empowering patients living with PAD, to seek timely wound care treatment critical for optimal healing and reducing the risk of amputations. Nearly 10 […]
Other News
Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CARLSBAD, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, granted an equity award on September 1, 2022 that was approved by the Compensation Committee of its Board […]
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on August 31, 2022 it granted stock options to purchase an aggregate of 186,400 shares of common stock to 23 new employees, whose employment commenced in August 2022, as a material inducement to […]
Viz.ai Receives FDA 510(k) Clearance for Automated RV/LV Analysis Algorithm
Part of the Viz PE Solution, new algorithm flags key patient risk indicator of pulmonary embolism severity SAN FRANCISCO–(BUSINESS WIRE)–Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an automated RV/LV ratio algorithm, a seamless […]
i-Cordis Receives SBIR Phase II Funding to Develop Treatment for Heart Failure with Preserved Ejection Fraction
BALTIMORE, Sept. 1, 2022 /PRNewswire/ — i-Cordis, LLC, an early-stage pharmaceutical company, has been awarded a Phase II Small Business Innovation Research (SBIR) grant for $1,548,708 from the National Heart, Lung, and Blood Institute (NHLBI) to further develop a potential immune-modulatory treatment for Heart Failure with preserved Ejection Fraction (HFpEF). HFpEF is one of […]
Venus Medtech announces 2022 interim results: quality and efficiency improvement, profitability focus, rapid progress in global presence
HANGZHOU, China, Sept. 1, 2022 /PRNewswire/ — On August 31, 2022, Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as “Venus Medtech”), a leading provider of integrated solutions for transcatheter structural heart valvular therapies in China, announced its interim results for the six months ended June 30, 2022. Under repeated COVID-19 outbreaks, Venus Medtech intensified its […]
Revealing Molecular Switches for Heart Disease
Michael Alexanian joins Gladstone Institutes to discover new targets for treating and reversing heart failure SAN FRANCISCO, Sept. 1, 2022 /PRNewswire/ — A healthy human heart is a powerful, pliable organ that expands and contracts rapidly to pump rich, oxygenated blood through the body. But for the millions of people around the world […]
St. Joseph’s Children’s Hospital First in Tampa Bay to Implant New Device That Narrows the Gap When it Comes to Transcatheter Heart Valve Repair
The innovative pre-stent standardizes the shape of the pulmonary valve opening, allowing for a higher number of patients to be candidates for transcatheter valve replacement. TAMPA, Fla., Aug. 30, 2022 /PRNewswire/ — Erin Ambrose knew the day would come. The day she would once again watch her daughter, Hailey, be wheeled into an operating […]
Sensifree Wins CE Certification for SentiCor-100® Continuous Non-Invasive Blood Pressure Monitor
KFAR SABA, Israel and SANTA CLARA, Calif., Aug. 31, 2022 /PRNewswire/ — Sensifree LTD, a world innovator in advanced hemodynamic monitoring (“Sensifree”), received CE certificate for SentiCor-100® in compliance with the new EU MDR. SentiCor-100® is the world’s first PPG based Continuous Non-Invasive Blood Pressure (cNIBP) monitoring device approved for hospital use. “This is an important landmark […]
JenaValve Raises $100 Million to Advance Trilogy TAVR Solution
Financing Secures Funding to Complete ALIGN-AR Clinical Trial, Continue E.U. Real World Evidence Development, and Prepare for a U.S. Commercial Launch IRVINE, Calif., Aug. 31, 2022 (GLOBE NEWSWIRE) — JenaValve Technology, Inc. (“JenaValve or the “Company”), developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, today announced that […]



